1. Within your trust how many patients have been treated with the following products in the past 3 months you have available;
MabThera IV (rituximab)
MabThera SC (rituximab)
Truxima (rituximab)
Gazyvaro (obinutuzumab)
Imbruvica (ibrutinib)
Zydelig (idelalisib)
Arzerra (ofatumumab)
2. Please can you state the number of patients for the above drugs for the following indications;
Follicular lymphoma [C82.0 to C82.9]
Diffuse Large B-cell Lymphoma [C83.3]
Chronic Lymphocytic Leukaemia [C91.1]
All other B-cell, haematological malignancies (all C82, C83, C85, C88.0, C88.4 codes not listed above]
Rheumatoid Arthritis [M5 and M6]
3. Does your trust code haematological malignancies against ICD10 codes?